Clinical guideline found no antipsychotic can be recommended over another for schizophrenia patients who use cannabis
Evidence-based guidelines using GRADE methodology found insufficient evidence to recommend any specific antipsychotic for schizophrenia patients with cannabis use disorder, while bupropion and varenicline were recommended for those with nicotine use.
Quick Facts
What This Study Found
For schizophrenia with cannabis use: no antipsychotic (olanzapine, risperidone, haloperidol, or clozapine) could be recommended over another (weak recommendation). For cocaine use: haloperidol reduced craving vs. olanzapine. For alcohol: naltrexone recommended. For nicotine: bupropion and varenicline recommended (strong/moderate). For polydrug: second-generation antipsychotics preferred.
Key Numbers
Cannabis+schizophrenia: no recommendation between olanzapine, risperidone, haloperidol (weak). Clozapine: cannot recommend for cannabis reduction (weak). Nicotine: bupropion and varenicline recommended (strong/moderate).
How They Did This
GRADE-based clinical practice guideline using systematic review of pharmacological and psychological interventions for adult schizophrenia patients with comorbid substance use disorders, structured by PICO framework.
Why This Research Matters
With high rates of cannabis use among schizophrenia patients, clinicians urgently need evidence-based guidance. The finding that no antipsychotic is clearly better for cannabis users highlights a critical evidence gap.
The Bigger Picture
The lack of evidence-based recommendations for the most common dual diagnosis (schizophrenia + cannabis) underscores the need for dedicated clinical trials in this population.
What This Study Doesn't Tell Us
Evidence quality was generally low to moderate. Limited number of head-to-head trials for cannabis + schizophrenia. Guidelines based on available evidence, which is sparse for cannabis-specific outcomes.
Questions This Raises
- ?Should dual diagnosis trials prioritize cannabis + schizophrenia given the prevalence?
- ?Would newer antipsychotics (cariprazine, brexpiprazole) perform differently?
Trust & Context
- Key Stat:
- No antipsychotic can be recommended over another for schizophrenia with cannabis use
- Evidence Grade:
- Rigorous GRADE methodology applied, but limited by the sparse available evidence for cannabis-specific recommendations.
- Study Age:
- Published in 2022.
- Original Title:
- Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.
- Published In:
- Adicciones, 34(2), 110-127 (2022)
- Authors:
- Arranz, Belen, Garriga, Marina(2), Bernardo, Miquel(10), González-Pinto, Ana, Arrojo, Manuel, Torrens, Marta, Tirado-Muñoz, Judith, Fonseca, Francina, Sáiz, Pilar A, Flórez, Gerardo, Goikolea, Jose Manuel, Zorrilla, Iñaki, Cunill, Ruth, Castells, Xavi, Becoña, Elisardo, López, Ana, San, Luis
- Database ID:
- RTHC-03683
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Which antipsychotic is best for schizophrenia patients who use cannabis?
Current evidence cannot recommend one over another. Olanzapine, risperidone, haloperidol, and clozapine all lack sufficient evidence for superiority in cannabis-using patients.
Are there any strong recommendations?
Yes, but for other substances: bupropion and varenicline received strong/moderate recommendations for schizophrenia patients with nicotine use disorder.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-03683APA
Arranz, Belen; Garriga, Marina; Bernardo, Miquel; González-Pinto, Ana; Arrojo, Manuel; Torrens, Marta; Tirado-Muñoz, Judith; Fonseca, Francina; Sáiz, Pilar A; Flórez, Gerardo; Goikolea, Jose Manuel; Zorrilla, Iñaki; Cunill, Ruth; Castells, Xavi; Becoña, Elisardo; López, Ana; San, Luis. (2022). Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.. Adicciones, 34(2), 110-127. https://doi.org/10.20882/adicciones.1504
MLA
Arranz, Belen, et al. "Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.." Adicciones, 2022. https://doi.org/10.20882/adicciones.1504
RethinkTHC
RethinkTHC Research Database. "Clinical practice guideline on pharmacological and psycholog..." RTHC-03683. Retrieved from https://rethinkthc.com/research/arranz-2022-clinical-practice-guideline-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.